ArticleJACC. Case reports2025
Mitral Valve Aspergillus Endocarditis With Aortal Embolization in an Immunocompetent Patient.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspergillus endocarditis is a rare condition. The clinical presentation is often atypical and insidious, resulting in delayed diagnosis and challenges in management. We report a case of native mitral valve Aspergillus endocarditis in an immunocompetent patient, with rare aortal embolization, who was managed in a multidisciplinary approach. Evidence for Aspergillus endocarditis is limited, and prospective data are unlikely to be available because of the low incidence of the disease. This case report adds great value to the current published case series to provide experience for clinicians when tackling similar conditions. Aspergillus endocarditis is rare but fatal. Cardiac surgery improves early survival, but long-term outcomes remain dismal. An endocarditis team with a multimodality approach is paramount to manage this difficult-to-treat disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.